Ludwig Enterprises, Inc. (LUDG)
| Previous Close | 0.2900 |
| Open | 0.2630 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.2630 - 0.2900 |
| 52 Week Range | 0.0620 - 0.5200 |
| Volume | |
| Avg. Volume | 8,970 |
| Market Cap | 46.116M |
| Beta (5Y Monthly) | 2.38 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- ACCESSWIRE
Ludwig Enterprises Inc (OTC:LUDG) Funds Incurable Brain Cancer Study
SPARKS, NV / ACCESSWIRE / March 27, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG): A US-based biotechnology company is pleased to announce that its subsidiary Exousia AI is funding a preclinical study on Glioblastoma (GBM), an incurable brain cancer. ...
GlobeNewswireLudwig Enterprises Inc (OTC:LUDG) Enters Booming Artificial Intelligence Cancer Screening Market with its Non-Invasive Cancer Diagnostics Testing Kit, launching within 2024
SPARKS, Nev., March 19, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc, (OTC: LUDG): A US-based biotechnology company is pleased to announce it has entered the booming artificial intelligence cancer screening market. The company, with its wholly owned subsidiary M-RNA for Life, has enlisted the help of the Director of Data Sciences at Nike Inc., Dr. Kyle Ambert PhD, to develop a cancer diagnostic test based on machine learning artificial intelligence (AI). Noninvasive buccal or cheek cells are
- GlobeNewswire
Ludwig Enterprises Inc. (OTC:LUDG) Announces Patent Filing for Breakthrough in Identifying mRNA Genes Associated with Certain Cancers
SPARKS, Nev., March 06, 2024 (GLOBE NEWSWIRE) -- Ludwig Enterprises, Inc. (OTC: LUDG): A US-based biotechnology company is pleased to announce the successful filing of its provisional patent, title “mRNAs differentially expressed in colorectal cancer, breast cancer, and bladder cancer.” By utilizing machine learning artificial intelligence (AI), this breakthrough is able identify specific mRNA genes associated with breast, colorectal, and bladder cancer. These genetic findings marks a significan
